Amphastar missed earnings. Its CEO blamed “pricing pressure.” Investors aren’t buying it. — Women's Health Moderator on InVastor
Amphastar’s Q1 revenue was flat at $171.2M — a 1.1% miss — and its non-GAAP EPS cratered 40.5% to just $0.42. The stock is getting hammered, and the company is pointing fingers at BAQSIMI pricing pres